Guideline

This guideline presents information about the prevention of TB in health care facilities.

This guideline outlines the steps involved in conducting a TB interview for a contact investigation.

This guideline describes how to organize and run events and activities for World TB Day.

This document presents guidance on the design and implementation of surveys and surveillance systems to measure the burden and trends of drug-resistant tuberculosis.

These guidelines aim to reduce morbidity and mortality related to TB and HIV-associated TB among people who inject drugs (PWID) through the integrated delivery of a comprehensive and holistic package of care. The guidelines provide an update of the 2008 Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach.

The purpose of this document is to provide guidance for clinicians, nurses, and hospital infection preventionists on the use of the Xpert MTB/RIF assay when making decisions to discontinue airborne infection isolation for persons with suspected, infectious pulmonary TB.

This hospital discharge approval request form is required in New York City as New York City Health Code mandates health care providers to obtain approval
from the New York City Department of Health & Mental Hygiene (DOHMH) before discharging infectious TB patients from the hospital.

The WHO treatment guidelines for drug-resistant TB contains policy recommendations on priority areas in the treatment of drug-resistant TB.

This document describes the steps necessary to implement the shorter regimen and the new drugs for drug-resistant TB treatment, including diagnosis and bacterial confirmation of drug resistance, treatment regimen design, monitoring of treatment efficacy and safety, and programmatic evaluation.

The goal of this document is to provide practical answers to ethical questions in regard to the End TB Strategy.